BioSpace News Archive

TFF Pharmaceuticals, Inc announced the closing of its previously announced public offering of an aggregate of 1,665,219 shares of its common stock and warrants to purchase up to 1,665,219 shares of common stock at a combined public offering price of $2.875 per share and accompanying warrant.

Metagenomi, Inc. announced it has regained full global rights to research, develop, manufacture, and commercialize its wholly-owned gene editing technologies, including base editors and RNA-mediated integration systems, which were previously subject to exclusive rights granted to Moderna, Inc.

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, May 14, 2024.

Galecto, Inc. announced that the first patient has been enrolled in an investigator-initiated Phase 2 trial to evaluate GB1211, Galecto’s first-in-class, oral small molecule galectin-3 inhibitor candidate, at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in Portland, Oregon, USA.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 10 newly-hired employees options to purchase an aggregate of 41,000 shares of Akebia’s common stock on April 30, 2024, as inducements material to such employee entering into employment with Akebia.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2024 and affirmed guidance for 2024.

Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”) today announced the presentation at Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2024) being held May 5 – 9, 2024, in Seattle, WA.

Accuray Incorporated reported financial results for the third quarter and nine-months ended March 31, 2024.

Envista Holdings Corporation announced results for the first quarter of 2024.

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024.